Post-traumatic stress disorder (PTSD) has been associated with negative effects on bone health, potentially leading to reduced bone mass, altered geometry, and impaired mechanical strength. However, the extent of these changes and possible pharmacological interventions remains unclear. This study aimed to assess the impact of PTSD on bone properties and evaluate the therapeutic potential of CE-123 in mitigating PTSD-induced skeletal deterioration. Additionally, we examined the effects of CE-123 on healthy bone to determine its broader influence on skeletal integrity and growth. Methods: We conducted an experiment using female Wistar rats divided into four groups: Control, PTSD, Control+CE-123, and PTSD+CE-123. PTSD was induced using a validated stress paradigm, and CE-123 was administered to evaluate its effects on bone properties. Morphometric, densitometric, and mechanical parameters of the tibia and femur were analyzed, along with growth plate measurements to assess potential effects on skeletal development. Results: PTSD led to significant reductions in bone mineral density, bone mass, and mechanical properties, particularly in cortical thickness and relative bone weight, suggesting increased bone fragility. CE-123 treatment in PTSD-exposed rats prevented some of these adverse effects but did not fully restore bone integrity. In healthy rats, CE-123 increased bone length and growth plate size, particularly in the proliferative and resting zones, indicating a stimulatory effect on bone growth. Conclusions: PTSD negatively affects bone structure and mechanical strength, while CE-123 shows a potential to mitigate these effects. However, its influence on healthy bones raises questions about its long-term impact on skeletal development. Further studies are needed to evaluate CE-123’s clinical applicability and safety, particularly in younger populations.